Cholinergic crisis

Active Ingredient: Atropine

Indication for Atropine

Population group: only adults (18 years old or older)

Treatment of cholinergic crisis of myasthenia gravis.

For this indication, competent medicine agencies globally authorize below treatments:

0.4-2 mg once

Route of admnistration

Intravenous

Defined daily dose

0.4 - 2 mg

Dosage regimen

From 0.4 To 2 mg once every day

Detailed description

The usual dose is 0.4 to 2.0mg intravenously, which may be increased according to patients response.

Active ingredient

Atropine

Atropine is an antimuscarinic agent which competitively antagonises acetylcholine at postganglionic nerve endings, thus affecting receptors if the exocrine glands, smooth muscle, cardiac muscle and the central nervous system.

Read more about Atropine

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner

Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.